Journal
CONTRACEPTION
Volume 72, Issue 3, Pages 168-174Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.contraception.2005.03.005
Keywords
NuvaRing; oral contraceptive; transdermal contraceptive patch; ethinylestradiol; pharmacokinetics
Categories
Ask authors/readers for more resources
This open-label, randomized study compared the pharmacokinetics of ethinylestradiol (EE) from the contraceptive vaginal ring NuvaRing (15 mu g EE/day), the transdermal patch (20 mu g EE/day) and a combined oral contraceptive (COC) containing 30 mu g EE. After 2-8 weeks of synchronization by COC treatment, subjects were randomized to 21 days of treatment with NuvaRing, patch or COC. Analysis of area under the EE concentration-versus-time curve (AUQ during 21 days of treatment showed that exposure to EE in the NuvaRing group was 3.4 times lower than in the patch group (p < .05) and 2.1 times lower than in the pill group (p < .05). Serum EE levels of subjects showed much lower variation with NuvaRing than with the patch or the COC. Thus, exposure to EE was significantly lower with NuvaRing than with the patch and pill methods, demonstrating that NuvaRing is a low-estrogen-dose contraceptive method that also results in low estrogen exposure. (c) 2005 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available